Comparison
3p Syndrome C4706503 vs 17 20 Lyase Deficiency Isolated C3277849
Clinical comparison between 3P Syndrome and 17 20 Lyase Deficiency Isolated for differential diagnosis and treatment planning.
3p Syndrome C4706503
A rare chromosomal disorder involving deletion of genetic material from chromosome 3. It causes distinctive facial features, growth delays, and intellectual disability. Care involves managing developmental and medical complications.
17 20 Lyase Deficiency Isolated C3277849
A rare enzymatic disorder affecting sex hormone production. Impairs development of sexual characteristics in both males and females. Treatment involves hormone supplementation.
6 comparison axes
Onset
3p Syndrome C4706503
0-0
17 20 Lyase Deficiency Isolated C3277849
0-18
Onset patterns differ
Severity
3p Syndrome C4706503
severe
17 20 Lyase Deficiency Isolated C3277849
severe
Different severity levels
Chronic
3p Syndrome C4706503
Chronic
17 20 Lyase Deficiency Isolated C3277849
Chronic
Differing course
Communicable
3p Syndrome C4706503
No
17 20 Lyase Deficiency Isolated C3277849
No
Different transmission
Body System
3p Syndrome C4706503
congenital
17 20 Lyase Deficiency Isolated C3277849
endocrine
Same/different system
Category
3p Syndrome C4706503
genetic
17 20 Lyase Deficiency Isolated C3277849
endocrine
Different category
Bottom line
3p-syndrome-C4706503 and 17-20-lyase-deficiency-isolated-C3277849 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3p Syndrome C4706503 | 17 20 Lyase Deficiency Isolated C3277849 | Discriminating power |
|---|---|---|---|
| Developmental pattern | Growth delay and intellectual disability are described. | Impaired sexual development is the main described feature. | High |
| Physical findings | Distinctive facial features may be present. | Facial features are not established by the supplied data. | Moderate |
| Pubertal or sexual development | Not specifically established from the supplied description. | Sexual characteristics may be underdeveloped in males and females. | High |
When to favor each condition
Choose 3p Syndrome C4706503 when
Congenital multisystem presentation
Chromosomal deletion better fits facial, growth, and developmental findings.
Moderate
Suspected genetic syndrome
The supplied category is genetic and the body system congenital.
High
Findings present from birth
The supplied onset axis is 0-0, suggesting congenital recognition.
Moderate
Choose 17 20 Lyase Deficiency Isolated C3277849 when
Disordered sexual development
The description centers on impaired sex-hormone production and sexual characteristics.
High
Endocrine evaluation
The supplied body system and category are endocrine.
High
Presentation during childhood or adolescence
The supplied onset range is 0-18, broader than birth-only recognition.
Moderate
How key tests differ
| Test | 3p Syndrome C4706503 | 17 20 Lyase Deficiency Isolated C3277849 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify deletion involving chromosome 3. | Not expected to establish this enzyme disorder. | A chromosomal result supports 3p syndrome but does not diagnose lyase deficiency. |
| Sex-steroid and precursor profile | No specific pattern is established here. | May suggest impaired sex-hormone production; exact cutoffs are not supplied. | Abnormal hormones are findings requiring specialist interpretation, not a diagnosis alone. |
| Targeted genetic or enzyme assessment | May support a chromosomal cause when deletion is confirmed. | May support an enzymatic cause when appropriately interpreted. | Test choice should follow clinical suspicion; neither result is defined here. |
Prognosis comparison
3p Syndrome C4706503
- Outcome
- Chronic congenital condition with developmental and medical needs; exact outcomes are not established.
- Factors
- Extent of deletion and associated complications may matter, but specifics are not supplied.
17 20 Lyase Deficiency Isolated C3277849
- Outcome
- Chronic endocrine condition; sexual development may improve with appropriate hormone care, but outcomes vary.
- Factors
- Timing of recognition and response to clinician-directed hormone supplementation may matter.
Time frame: Both are described as chronic; no mortality or fixed timeline is established.
Etiology, affected system, complications, and access to specialist care influence course.
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental complications | Developmental and medical complications may require ongoing care. Not established as a primary feature in the supplied description. Support needs differ and should be individualized. |
| Growth concerns | Growth delay is described. Growth effects are not established from the supplied data. Do not infer a specific growth pattern for the enzyme disorder. |
| Sexual-development concerns | Not specifically established here. Impaired sexual characteristics may occur and may need hormone supplementation. Doses and regimens are not supplied and require clinician direction. |
Patient education highlights
- HighDifferent causes
One is a chromosomal deletion; the other is an enzyme disorder affecting sex hormones.
- HighSpecialist care
Genetics, endocrinology, and developmental clinicians may be needed depending on findings.
- MediumTest meaning
An abnormal test is not automatically a diagnosis and needs clinical correlation.